M&A / J&J’s Momenta Deal A Further Sign of Big Pharma’s Rare Disease Push
In the wake of Sanofi’s USD 3.7 billion tie-up for US biotech Principia, J&J has moved to bolster its autoimmune portfolio with the acquisition of Momenta Pharmaceuticals for USD 6.5…